医学
重症监护医学
围手术期
指南
恶化
肺癌
特发性肺纤维化
肺
临床实习
生活质量(医疗保健)
干预(咨询)
新辅助治疗
内科学
物理疗法
工作队
临床试验
阶段(地层学)
放射治疗
肿瘤科
相伴的
入射(几何)
循证实践
随机对照试验
中止
梅德林
风险评估
循证医学
外科
癌症
多学科方法
系统回顾
作者
Argyris Tzouvelekis,Merel E. Hellemons,Charlotte Billiet,Torsten Gerriet Blum,Jacquès Cadranel,Laura Fabbri,Sabina A. Guler,Julien Guiot,Georgia Hardavella,Nils Hoyer,Steve Jones,Atsushi Miyamoto,Joyce Sujin Lee,Sara Piciucchi,Sara Ricciardi,Anne-Marie Russell,Ilona Tietzova,Thomy Tonia,Juan Carlos Trujillo-Reyes,Carlo Vancheri
出处
期刊:PubMed
[National Institutes of Health]
日期:2026-11-19
标识
DOI:10.1183/13993003.01271-2026
摘要
BACKGROUND: Managing patients with idiopathic pulmonary fibrosis (IPF) and concomitant lung cancer is a major clinical challenge due to increased incidence and negative impact on quality of life and mortality. Evidence-based recommendations are lacking. This European Respiratory Society (ERS) clinical practice guideline provides recommendations to balance oncological benefits against treatment-associated toxicity. METHODS: An ERS multidisciplinary Task Force of experts and patient representatives produced 11 conditional recommendations across seven PICO (Population, Intervention, Comparison, Outcome) questions and two narrative questions; for one PICO question no recommendation was issued. Systematic reviews were performed for each question. Evidence certainty was assessed using the GRADE (Grading of Recommendations, Assessment, Development and Evaluation) approach (for PICOs) and recommendations were formulated using the Evidence-to-Decision framework. RESULTS: For early-stage lung cancer, the Task Force suggests surgical resection in medically fit patients. Postoperative risk necessitates systematic preoperative evaluation, perioperative antifibrotic therapy discussion and protective perioperative strategies. For stereotactic radiotherapy, a conditional recommendation for either the intervention or the comparison was issued, balancing potential oncological benefit against radiation pneumonitis. In locally advanced lung cancer, the Task Force suggests not administering concurrent radio-chemotherapy, due to very high acute exacerbation rates. For advanced lung cancer, chemotherapy is suggested in medically fit patients, where survival benefits outweigh increased toxicity risks. For stage IV lung cancer, evidence for immunotherapy was limited, thus a conditional recommendation for either the intervention or the comparison was issued. Evidence for targeted therapy for lung cancer in patients with IPF was insufficient to support a recommendation. CONCLUSION: Given the poor prognosis of both conditions and treatment-associated risks, management requires multidisciplinary assessment of competing risks and patient preferences in experienced interstitial lung disease and oncology centres.
科研通智能强力驱动
Strongly Powered by AbleSci AI